The Danish laboratory anticipates another year of robust double-digit growth in sales and operating profit, while beginning to ease restrictions on the supply of its popular weight loss drug, Wegovy..
Novo Nordisk will target launches of its popular obesity shot Wegovy in markets where it already has strong sales of its older weight-loss drug Saxenda, CEO Lars Fruergaard.
Novo Nordisk will more than double supplies of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on.
Novo Nordisk will
target launches of its mega popular obesity shot Wegovy in
markets where it already has strong sales of its older
weight-loss drug Saxenda, CEO Lars Fruergaard Jorgensen said, as
it.
International Business News: The European Commission published its first list of critical medicines, as part of a wider overhaul of laws governing the 136 billion euro ($148 billi